Sensei Biotherapeutics reported full year 2025 financial results on March 30, 2026, following the acquisition of Faeth Therapeutics.
Acquired Faeth adds PIKTOR, an all-oral combination product candidate targeting the PI3K/AKT/mTOR pathway.
Completed $200 million private placement to support clinical milestones in endometrial and breast cancer.
Cash, cash equivalents, and marketable securities were $21.2 million as of December 31, 2025, excluding private placement proceeds.
Net loss narrowed to $21.1 million ($16.72 per share) in 2025 from $30.2 million ($24.01 per share) in 2024.
Plans include topline data from Phase 2 trial in advanced endometrial cancer and Phase 1b initiation in HR+/HER2- breast cancer by end of 2026.